|
1.
|
Clapham PR, Lu S. Vaccinology: precisely tuned antibodies nab HIV. Nature. 2011; 477(7365):416-7.
|
|
|
|
|
2.
|
E X, Pickering MT, Debatis M, Castillo J, Lagadinos A, Wang S, Lu S, Kowalik TF. An E2F1-Mediated DNA Damage Response Contributes to the Replication of Human Cytomegalovirus. PLoS Pathog. 2011 May; 7(5):e1001342.
|
|
|
|
|
3.
|
Vaine M, Duenas-Decamp M, Peters P, Liu Q, Arthos J, Wang S, Clapham P, Lu S. Two Closely Related Env Antigens from the Same Patient Elicited Different Spectra of Neutralizing Antibodies against Heterologous HIV-1 Isolates. J Virol. 2011 May; 85(10):4927-36.
|
|
|
|
|
4.
|
Wang S, Goguen JD, Li F, Lu S. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge. Vaccine. 2011 Sep 9; 29(39):6802-9.
|
|
|
|
|
5.
|
Lu S, Wang S, Grimes Serrano JM. Polyvalent AIDS vaccines. Curr HIV Res. 2010 Dec 1; 8(8):622-9.
|
|
|
|
|
6.
|
Vaine M, Wang S, Liu Q, Arthos J, Montefiori D, Goepfert P, McElrath MJ, Lu S. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS One. 2010; 5(11):e13916.
|
|
|
|
|
7.
|
Wang Z, Zhang M, Wang Y, Jiao Y, Zhang L, Li L, Huang Z, Wu H, Li J, Lu S, Wang S. A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates. J Virol Methods. 2011 Jan; 171(1):183-9.
|
|
|
|
|
8.
|
Wang S, Mboudjeka I, Goguen JD, Lu S. Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines. Vaccine. 2010 Feb 23; 28(8):2011-9.
|
|
|
|
|
9.
|
Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine. 2010 Apr 9; 28(17):2999-3007.
|
|
|
|
|
10.
|
Abdel-Motal UM, Wang S, Awad A, Lu S, Wigglesworth K, Galili U. Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes. Vaccine. 2010 Feb 17; 28(7):1758-65.
|
|
|
|
|
11.
|
Lu S, Wang S. Technical transformation of biodefense vaccines. Vaccine. 2009 Nov 5; 27 Suppl 4:D8-D15.
|
|
|
|
|
12.
|
Lu S. Gene-based adjuvants: a new meaning. Hum Gene Ther. 2009 Oct; 20(10):1101-2.
|
|
|
|
|
13.
|
Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009 Jun; 21(3):346-51.
|
|
|
|
|
14.
|
Vaine M, Lu S, Wang S. Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). BioDrugs. 2009; 23(3):137-53.
|
|
|
|
|
15.
|
Lu S. Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin. 2008 Nov-Dec; 4(6):449-52.
|
|
|
|
|
16.
|
Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, Arthos J, Pal R, Markham P, Lu S. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine. 2008 Jul 23; 26(31):3947-57.
|
|
|
|
|
17.
|
Kennedy JS, Co M, Green S, Longtine K, Longtine J, O'Neill MA, Adams JP, Rothman AL, Yu Q, Johnson-Leva R, Pal R, Wang S, Lu S, Markham P. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine. 2008 Aug 18; 26(35):4420-4.
|
|
|
|
|
18.
|
Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, Lu S. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol. 2008 Aug; 82(15):7369-78.
|
|
|
|
|
19.
|
Wang S, Parker C, Taaffe J, Solórzano A, García-Sastre A, Lu S. Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine. 2008 Jul 4; 26(29-30):3626-33.
|
|
|
|
|
20.
|
Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines. 2008 Mar; 7(2):175-91.
|
|
|
|
|
21.
|
Wang S, Joshi S, Mboudjeka I, Liu F, Ling T, Goguen JD, Lu S. Relative immunogenicity and protection potential of candidate Yersinia Pestis antigens against lethal mucosal plague challenge in Balb/C mice. Vaccine. 2008 Mar 20; 26(13):1664-74.
|
|
|
|
|
22.
|
Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, Arthos J, Pal R, Markham P, Lu S. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine. 2008 Feb 20; 26(8):1098-110.
|
|
|
|
|
23.
|
Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology. 2008 Feb 5; 371(1):98-107.
|
|
|
|
|
24.
|
Pouliot K, Pan N, Wang S, Lu S, Lien E, Goguen JD. Evaluation of the role of LcrV-Toll-like receptor 2-mediated immunomodulation in the virulence of Yersinia pestis. Infect Immun. 2007 Jul; 75(7):3571-80.
|
|
|
|
|
25.
|
Shen S, Wang S, Britt WJ, Lu S. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates. Vaccine. 2007 Apr 30; 25(17):3319-27.
|
|
|
|
|
26.
|
Lu S. Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol. 2006 Nov; 28(3):255-65.
|
|
|
|
|
27.
|
Wang S, Taaffe J, Parker C, Solórzano A, Cao H, García-Sastre A, Lu S. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol. 2006 Dec; 80(23):11628-37.
|
|
|
|
|
28.
|
Sakhatskyy P, Wang S, Chou TH, Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology. 2006 Nov 25; 355(2):164-74.
|
|
|
|
|
29.
|
Biswas S, Langeveld JP, Tipper D, Lu S. Intracellular accumulation of a 46 kDa species of mouse prion protein as a result of loss of glycosylation in cultured mammalian cells. Biochem Biophys Res Commun. 2006 Oct 13; 349(1):153-61.
|
|
|
|
|
30.
|
Abdel-Motal U, Wang S, Lu S, Wigglesworth K, Galili U. Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes. J Virol. 2006 Jul; 80(14):6943-51.
|
|
|
|
|
31.
|
Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, Kalyanaraman VS, Markham P, Lu S. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology. 2006 Jun 20; 350(1):34-47.
|
|
|
|
|
32.
|
Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, Lu S. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine. 2006 May 22; 24(21):4531-40.
|
|
|
|
|
33.
|
Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, Shen S, Chou TH, Montefiori DC, Lu S. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol. 2005 Jun; 79(12):7933-7.
|
|
|
|
|
34.
|
Wang S, Sakhatskyy P, Chou TH, Lu S. Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV). J Immunol Methods. 2005 Jun; 301(1-2):21-30.
|
|
|
|
|
35.
|
Chou TH, Wang S, Sakhatskyy PV, Mboudjeka I, Mboudoudjeck I, Lawrence JM, Huang S, Coley S, Yang B, Li J, Zhu Q, Lu S. Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology. 2005 Mar 30; 334(1):134-43.
|
|
|
|
|
36.
|
Wang S, Chou TH, Sakhatskyy PV, Huang S, Lawrence JM, Cao H, Huang X, Lu S. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol. 2005 Feb; 79(3):1906-10.
|
|
|
|
|
37.
|
Wang S, Heilman D, Liu F, Giehl T, Joshi S, Huang X, Chou TH, Goguen J, Lu S. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine. 2004 Sep 3; 22(25-26):3348-57.
|
|
|
|
|
38.
|
Liu F, Mboudjeka I, Shen S, Chou TH, Wang S, Ross TM, Lu S. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model. Vaccine. 2004 Apr 16; 22(13-14):1764-72.
|
|
|
|
|
39.
|
Chou TH, Biswas S, Lu S. Gene delivery using physical methods: an overview. Methods Mol Biol. 2004; 245:147-66.
|
|
|
|
|
40.
|
Wang S, Joshi S, Lu S. Delivery of DNA to skin by particle bombardment. Methods Mol Biol. 2004; 245:185-96.
|
|
|
|
